Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction

Pharmacotherapy

Volumn 30, Issue 1, 2010, Pages 52-56

  Jain, Lokesh ^a   Gardner, Erin R ^c   Figg, William D ^a   Chernick, Milica S ^b   Kong, Heidi H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c SAIC FREDERICK INC   (United States)

Author keywords

Hand foot skin reaction; Hand foot syndrome; Sorafenib; Sweat

Indexed keywords

BEVACIZUMAB; PILOCARPINE; SORAFENIB;

ADULT; ARTICLE; CANCER RESEARCH; CASE REPORT; DISEASE ASSOCIATION; DRUG EXCRETION; FEMALE; HAND FOOT SYNDROME; HUMAN; HUMAN EXPERIMENT; IONTOPHORESIS; LIQUID CHROMATOGRAPHY; MALE; NORMAL HUMAN; OUTPATIENT DEPARTMENT; PROSPECTIVE STUDY; SWEATING; TANDEM MASS SPECTROMETRY;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG ERUPTIONS; FEMALE; FOOT DERMATOSES; HAND DERMATOSES; HUMANS; IONTOPHORESIS; LIMIT OF DETECTION; MALE; MIDDLE AGED; PILOCARPINE; PILOT PROJECTS; PROTEIN KINASE INHIBITORS; PYRIDINES; SEVERITY OF ILLNESS INDEX; SWEAT; TANDEM MASS SPECTROMETRY;

EID: 75149159274     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.1.52     Document Type: Article

References (14)

1. Azad NS, Aragon-Ching JB, Dahut WL, et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res 2009;15:1411-16.
2. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34.
3. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
4. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-12.
5. Jacobi U, Waibler E, Schulze P, et al. Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome? Ann Oncol 2005;16:1210-11.
6. Mastella G, Di Cesare G, Borruso A, Menin L, Zanolla L. Reliability of sweat-testing by the Macroduct collection method combined with conductivity analysis in comparison with the classic Gibson and Cooke technique. Acta Paediatr 2000;89:933-7.
7. Jain L, Gardner ER, Venitz J, Dahut W, Figg WD. Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma. J Pharm Biomed Anal 2008;46:362-7.
8. Bayer Health Care Pharmaceuticals, Inc. Sorafenib (Nexavar) prescribing information. Wayne, NJ; 2009. Available from http://www.nexavar.com/ html/download/Nexavar-PI.pdf. Accessed June 15, 2009.
9. Strumberg D, Clark JW, Awada A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007;12:426-37.
10. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-38.
11. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516-24.
12. Drug Bank. Drug cards for sorafenib (DB00398), sunitinib (DB01268), doxorubicin (DB00997), fluorouracil (DB00544), cytarabine (DB00987), hydroxyurea (DB01005) and capecitabine (DB1101). Available from http://www.drugbank.ca/. Accessed June 15, 2009.
13. Lacouture ME, Reilly LM, Gerami P, Guitart J. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 2008;19: 1955-61.
14. Yang CH, Lin WC, Chuang CK, et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 2008;158:592-6.